T/GXAS 847-2024 Active Group standards

T/GXAS 847-2024 Non-small cell lung cancer immune checkpoint inhibitor-associated pneumonia management and treatment guidelines

T/GXAS 847-2024 Non-small cell lung cancer immune checkpoint inhibitor-associated pneumonia management and treatment guidelines

Publish Date: 2024-10-14 Implement Date: 2024-10-20 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us
Price: $ 20.00
Out of stock

Basic Information

Standard Code: T/GXAS 847-2024
Standard Type: Group standards
Standard Status: Active
is_force_gb: no
CCS Name: Medicine, health, and labor protection
ICS Name: Integrated medical science and healthcare devices
Publish Date: 2024-10-14
Implement Date: 2024-10-20

Scope

Scope: This document defines the terms and definitions related to the diagnosis and treatment of immun checkpoint inhibitor-induced pneumonia in non-small cell lung cancer, provides abbreviations, and stipulates the requirements for diagnosis, syndrome differentiation, and treatment. This document is applicable to the diagnosis and treatment of immun checkpoint inhibitor-induced pneumonia in non-small cell lung cancer. Main technical content: This document defines the terms and definitions related to the diagnosis and treatment of immun checkpoint inhibitor-induced pneumonia in non-small cell lung cancer, provides abbreviations, and stipulates the requirements for diagnosis, syndrome differentiation, and treatment. This document is applicable to the diagnosis and treatment of immun checkpoint inhibitor-induced pneumonia in non-small cell lung cancer.

Development Information

Related Standards

Contact Us